Walmar Clinical ApS: Financial statements 2023
CVR: 43237381
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Walmar Clinical ApS (CVR 43237381) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 1,909,543 and a net result of DKK 725,164. Equity in the 2023 report amounted to DKK 775,310. The solvency ratio was 36.6%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,909,543
- Profit/Loss
- DKK 725,164
- Equity
- DKK 775,310
- Total Assets
- DKK 2,120,824
- Employees
- 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Walmar Clinical ApS has published its interim report for the period May 3, 2022 – December 31, 2022.
As of March 15, 2023, 26c Holding ApS is registered as an owner of Walmar Clinical ApS with an ownership share of 100%.
About Walmar Clinical ApS
Walmar Clinical ApS is a Danish company of the type Anpartsselskab based in Snekkersten, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Mikkel Walmar. The company is owned by 26c Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 1,847,721 and a net result of DKK 527,965 compared with DKK 623,346 the year before. Equity in the 2025 report amounted to DKK 932,122.